TABLE 1 .
List of microbial strains and cell lines used in this study
| Species by category | Strain | Resistancea |
|---|---|---|
| Spectrum of activity screens | ||
| Gram positive | ||
| Bacillus subtilis | 168 1A1 (BGSC) | |
| Enterococcus faecium | Com15 | |
| Enterococcus faecalis | Brady lab strain | V |
| Staphylococcus aureus | USA300 | M |
| Streptococcus sobrinus | W1703 (BEI) | |
| Lactobacillus rhamnosus | LMS2-1 (BEI) | |
| Gram negative | ||
| Acinetobacter baumanni | ATCC 17978 | |
| Enterobacter cloacae | ATCC 14037 | |
| Escherichia coli | DH5α | |
| Klebsiella pneumoniae | ATCC 10031 | |
| Pseudomonas aeruginosa | PAO1 | |
| Salmonella enterica | Subsp. enterica | |
| Cytotoxicity assessment | ||
| Candida albicans | Brady lab strain | |
| Homo sapiens | HT-29 (BEI) | |
| Clinical isolates used in this studyb | ||
| Acinetobacter baumannii | 1788 | C, E, T |
| 1790 | C, E, T | |
| 1791 | C, E, T | |
| 1795 | C, E, T | |
| 1797 | C, E, T | |
| S3 | C, E | |
| S5 | C, E | |
| AB5075 | T | |
a
Resistance abbreviations: C, cephalexin; E, ertapenem; M, methicillin; T, tetracycline; V, vancomycin.
b
The clinical isolates used in this study are described in more detail in references 19, 20, and 22. Strains 1788 to 1797 and S3 and S5 are independent drug-resistant isolates: strains 1788 to 1797 are from the Hospital for Special Surgery (New York, NY), and strains S3 and S5 are from the clinical laboratory of Ohio State University Hospital (Columbus, OH).